May 6, 2015 – Jerusalem, Israel — BioCancell Ltd. (TASE:BICL) today announced that it had filed an international patent request under the Patent Cooperation Treaty (PCT), describing a new formulation for its drug BC-819 as a ready-to-use powder. The primary advantages of this formulation are:
The new form is designed to simplify treatment preparation. This preparation previously required mixing BC-819 with PEI (Polyethelenamine, a polymer that aids in drug transfection into bladder cells) at the patient’s bedside immediately before administration. This was a complicated and sensitive procedure, which required training and skill on the part of the medical team.
The new form matches the accepted method of treatment in hospitals and clinics, and its use is expected to improve market penetration, once the drug is approved for marketing.
The patent request is based on a product claim, expected to provide the strongest type of protection. If approved, it will provide 20 years of intellectual property protection.
This press release contains “forward-looking” statements, including statements with respect to the further development and potential safety and efficacy of BC-819, in the treatment of superficial bladder cancer and BioCancell’s development strategy. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of BioCancell to differ materially from those indicated by these forward-looking statements, including, among others, the risk that the U.S. Food and Drug Administration may require changes to the protocols and informed consents for clinical trials of BC-819, which changes may have a material adverse effect on the timing of, and BioCancell’s ability to conduct, those clinical trials, risks related to the clinical advancement of its BC-819 plasmid, including, but not limited, to the risk that clinical trials for this product candidate may not demonstrate safety and efficacy sufficient to obtain the requisite regulatory approvals or to result in a marketable product and risks related to the potential for others to develop products containing or based on BC-819. BioCancell does not undertake any obligation to update forward-looking statements.